2023JUL10 Issue Briefs Challenges Facing China after the Ukraine War and Its Responses By Lee Dong Gyu [Issue Brief Executive Summary] Lee Dong Gyu Tags : ‘One China’, Authoritarian States, BRI, China, nuclear weapons, Russia, Taiwan, U.S., Ukraine War
2023JUN12 Blog/Op-ed [JoongAng Sunday] Living in an era of 25 percent peace probability By Yoon Young-kwan Yoon Young-kwan, Chairman Tags : AI, China, decoupling, derisking, EU, U.S., U.S.-China
2023MAR08 Publications Southeast Asian Perspectives of the United States and China : A SWOT Analysis By Lee Jaehyon [Asan Report] Lee Jaehyon Tags : ASEAN, AUKUS, Biden, Indo-Pacific, Malaysia, Singapore, SWOT, Thailand, US-China
2022DEC12 Issue Briefs Xi Jinping’s Third Term, the Outlook for China’s Domestic and Foreign … By Lee Dong Gyu [Issue Brief Executive Summary] Lee Dong Gyu Tags : BRICS, CCP, China, SCO, South Korea, Xi Jinping, Zero-COVID policy
2022AUG23 Issue Briefs South Korea Needs to Properly Respond to China’s ‘Five Points’ [Issue Brief] The Asan Institute for Policy Studies Tags : Five Points, Korea-China relations, Wang Yi, Yoon Suk-yeol administration
2022AUG18 Past Events A Meeting with the Representative of Taipei Mission in Korea Tags : Kuang-Chung Liang, Lee Joon-gyu, South Korea, Taipei
2022JUL29 Issue Briefs How Should the Yoon Administration Approach China? By Lee Dong Gyu [Issue Brief Executive Summary] Lee Dong Gyu Tags : China, COVID-19, IPEF, KADIZ, Moon Jae-In, THAAD, U.S.-China competition, Yoon Suk-yeol
2022APR11 Issue Briefs Political and Diplomatic Implications of China’s Two Sessions 2022 By Lee Dong Gyu [Issue Brief Executive Summary] Lee Dong Gyu Tags : CCP, China, COVID-19, CPPCC, Li Keqiang, NPC, Russia, Xi Jinping
2021DEC13 Issue Briefs Prospects for the Taiwan Issue in the Era of U.S.-China Strategic Competition By Lee Dong Gyu [Issue Brief Executive Summary] Lee Dong Gyu
2021JUL14 Issue Briefs The Perils of Openness? South Korea’s Quarantine Exemption for Chinese … By Lee Dong Gyu [Issue Brief Executive Summary] Lee Dong Gyu Tags : Chinese Vaccines, COVID-19, MFDS, Sinopharm, Sinovac, South Korea, US-China vaccine competition, WHO
